Best Practices and Research Advances in Thoracic Oncology: A Regional Series LATAM Course 1: Liquid Biopsy in Lung Cancer-Adequate Technology for Liquid Biopsy

Video Transcription

Video Summary

Valeria Denninghoff discusses the technology for liquid biopsy, focusing on detecting DNA mutations in blood. She highlights the use of real-time PCR, digital PCR, and next-generation sequencing (NGS) for identifying genetic alterations, emphasizing NGS's sensitivity. She mentions challenges like varying DNA concentrations and recommends automated NGS library preparation. Denninghoff notes that only a few FDA-approved tests exist, with laboratory-developed tests (LDT) being prevalent. Quality control and inter-laboratory validation are crucial. The discussion covers different DNA sequencing methodologies and the importance of choosing technologies aligned with economic realities and clinical needs.

Asset Subtitle

Valeria Denninghoff, PhD

Keywords

liquid biopsy

DNA mutations

next-generation sequencing

laboratory-developed tests

quality control